Clinical trials: Transgender Persons
Transgender Persons
Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
Purpose. The purpose of this research is study the effect of progesterone therapy on testosterone levels in transwomen who are currently on gender affirming treatment with estradiol. Duration.
- Trial name
- NCT04534881
- Testing
- Progesterone 200 MG
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Louis University
HIV I Infection
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
Transgender women (TW) are a key population and priority for HIV treatment. More research is needed to develop evidence-based clinical guidance when it comes to choosing antiretroviral treatment (ART) regimens for TW on…
- Trial name
- GETITRIgHT (NCT06005610)
- Testing
- Estradiol
- Where
- 18 sites in United States, Mexico and 2 more
- Volunteers
- 93 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Sexually Transmitted Diseases
Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment
The overall goal of this 3-arm randomized trial is to test whether a network-driven online intervention tailored for intersectional stigma amelioration can elicit online social support, promote intervention engagement, and…
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Stigma, Social
- Trial name
- NCT03678181
- Testing
- Information Resources, Social Support, HIV Testing
- Where
- 3 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections, HIV Primary Infection
A Couples-based Intervention for Transgender Women and Their Partners
This project seeks to test the efficacy of a couples-based HIV prevention program in large-scale randomized controlled trial (RCT) to reduce HIV risk among transgender woman and their partners.
- Trial name
- T2 (NCT04067661)
- Testing
- CHIP, Control
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HIV
Promoting Viral Suppression Among Transgender Women Living With HIV in Santo Domingo
This study includes an adapted multilevel intervention, Abriendo Puertas (Opening Doors), including individual counseling, peer navigation, and community mobilization for transfeminine people living with HIV in the Dominican…
- Trial name
- NCT06316102
- Testing
- Gender Affirming Abriendo Puertas (Opening Doors) (GAP)
- Where
- Dominican Republic
- Volunteers
- 139 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Preexposure Prophylaxis
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who…
- Trial name
- Impower-024 (NCT04652700)
- Testing
- ISL, FTC/TDF, FTC/TAF
- Where
- 25 sites in United States, Brazil and 5 more
- Volunteers
- 494 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS, Health Knowledge, Attitudes, Practice
Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health-related Behavior Among Transgender Women
The study is a 2-arm cluster randomized controlled trial to be conducted with 450 trans women to assess the effectiveness of the Trans Women Connected mobile app.
- Conditions
- HIV/AIDS, Health Knowledge, Attitudes, Practice, STI
- Trial name
- TWC (NCT03897049)
- Testing
- Trans Women Connected, General Health App
- Where
- United States
- Volunteers
- 574 people, healthy volunteers welcome
- Sponsor
- ETR Associates
HIV Infections
(mo)BETTA Trial in Transwomen for Optimization of ART
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected…
- Trial name
- (mo)BETTA (NCT03348163)
- Testing
- B/FTC/TAF, Current ART
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV Prevention, Transgender Health
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012. Drug concentrations after receipt of oral Truvada for HIV Pre Exposure Prophylaxis (or PrEP) appeared to be…
- Trial name
- I-BrEATHe (NCT04050371)
- Testing
- 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth…
- Trial name
- PURPOSE 2 (NCT04925752)
- Testing
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN)
- Where
- 93 sites in United States, Argentina and 6 more
- Volunteers
- 3,292 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Tobacco-Related Carcinoma
Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults
This trial refines and evaluates anti-tobacco messages among lesbian, gay, bisexual, and transgender (LGBT) young adults at risk for the use of more than one tobacco product (polytobacco use).
- Trial name
- NCT05393869
- Testing
- Health communications
- Where
- United States
- Volunteers
- 2,849 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center